Topical application of NADH for the treatment of rosacea and contact dermatitis

Clinical and Experimental Dermatology

Volumn 28, Issue 1, 2003, Pages 61-63

  Wozniacka A ^a   Sysa Jedrzejowska A ^a,b   Adamus, J ^b   Gebicki J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; FREE RADICAL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ADULT; AUTOIMMUNE DISEASE; CATALYSIS; CLINICAL ARTICLE; CONTACT DERMATITIS; DRUG EFFECT; ELECTRON TRANSPORT; ENZYME METABOLISM; FEMALE; HUMAN; HYDRATION; HYDROPHOBICITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; ROSACEA;

ADULT; ARM; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, CONTACT; FACIAL DERMATOSES; FEMALE; HUMANS; MALE; MIDDLE AGED; NAD; OINTMENTS; ROSACEA;

EID: 0037278198     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2003.01118.x     Document Type: Review

References (20)

1. Lehninger AL. Vitamins and coenzymes. Biochemistry, 2nd edn. Worth Publishers, Inc. New York, 1975: 337-42.
2. Kirsch M, De Groot H. NAD(P)H, a directly operating antioxidant?. FASEB J 2001; 15: 1569-74.
3. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human diseases: an overview. Methods Enzymol 1990: 186: 1-85.
4. Maccarrone M, Cotani MV, Iraci S et al. A survey of reactive oxygen species and their role in dermatology. J Europ Acad Dermat Venerol 1997; 8: 185-202.
5. Johnson SL. Acid-catalyzed hydration of reduced nicotinamide adenine dinucleotide and its analogues. Biochemistry 1977; 16: 1175-88.
6. Miksic JR, Brown PR. Reactions of reduced nicotinamide dinucleotide in acid: studies by reversed-phase high-pressure liquid chromatography. Biochemistry 1978; 17: 2234-8.
7. Acheson SA, Kirkman HN, Wolfenden R. Equilibrium of 5,6-hydration of NADH and mechanism of ATP-dependent dehydration. Biochemistry 1988; 27: 7371-5.
8. Gebicki J, Marcinek A, Adamus J et al. Structural aspects and rearrangement of radical cations generated from NADH analogues. J Am Chem Soc 1996; 118: 691-2.
9. Marcinek A, Adamus J, Gebicki J et al. Hydrogen-transferred radical cations of NADH model compounds. 1. Spontaneous tautomerization. J Am Chem Soc 2000; 122: 437-43.
10. +. J Phys Chem 2000; 104: 718-23.
11. Marcinek A, Adamus J, Gebicki J et al. Hydrogen-transferred radical cations of NADH model compounds. 3. 1,8-Acridinediones. J Phys Chem 2000; 104: 724-8.
12. Adamus J, Gebicki J, Ciebiada I et al. 3,6-diamino-10-methylacridan: uncharged precursor of acriflavine and its unique antimicrobial activity. J Med Chem 1998; 41: 2932-3.
13. Birkmayer JGD. Stable, ingestable and absorbable NADH and NADPH therapeutic composition. United States Patent. 5,332,727.1994.
14. Birkmayer W, Birkmayer GJD, Vrecko K et al. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of Parkinsonian patients. J Neural Trans (P-D Sect) 1989; 1: 297-302.
15. Birkmayer W, Birkmayer GJD. Nicotinamide adenine dinucleotide (NADH). the new approach in the therapy of Parkinson's disease. Ann Clin Laboratory Sci 1989; 19: 38-43.
16. Birkmayer JG, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH) - a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl 1993; 146: 32-5.
17. Birkmayer JGD. The new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Laboratory Sci 1996; 26: 1-9.
18. Busheri N, Jarrel ST, Lieberman S et al. Oral reduced β-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR). Geriatr Nephrol Urol 1998; 8: 95-100.
19. Forsyth LM, Preuss HG, MacDowell AL et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 1999 February; 82: 185-91.
20. Birkmayer JGD, Birkmayer W. The coenzyme nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent. Experience with 205 patients. New Trends Clin Neuropharmacol 1991; 5: 75-86.